Kuaiyi Biopharmaceutical Technology

Kuaiyi Biopharmaceutical Technology is a China-based biotechnology company specializing in the development of innovative small molecule drugs, with a primary focus on Proteolysis-Targeting Chimera (PROTAC) technology. The company leverages its proprietary platform to design degraders for historically undruggable targets or to overcome resistance mechanisms in existing therapies. Its current research and development efforts are concentrated on oncology, particularly targeting hormone-driven cancers such as prostate and breast cancer. Kuaiyi aims to provide next-generation precision medicine by utilizing targeted protein degradation to achieve superior clinical outcomes compared to traditional inhibitors.